N-acetylkynurenine | 3428-08-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-acetylkynurenine
• 英文别名: (S)-2-acetylamino-4-(2-amino-phenyl)-4-oxo-butyric acid；(S)-2-Acetylamino-4-(2-amino-phenyl)-4-oxo-buttersaeure；(2S)-2-acetamido-4-(2-aminophenyl)-4-oxobutanoic acid
• CAS: 3428-08-8
• 化学式: C₁₂H₁₄N₂O₄
• 分子量: 250.254
• InChiKey: PPIMFXHQDQRWGJ-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] TREATMENT OF DISEASE WITH N-ACETYL KYNURENINE<br/>[FR] TRAITEMENT D'UNE MALADIE AVEC DE LA N-ACÉTYL-KYNURÉNINE
  申请人：AMPIO PHARMACEUTICALS INC

  公开号：WO2018044724A1

  公开（公告）日：2018-03-08

  The invention provides a method, composition and kit for treating T-cell mediated diseases, degenerative joint diseases or diseases mediated by platelet activating factor (PAF) comprising administering to an animal in need thereof, an effective amount a pharmaceutical composition containing N-acetyl-kynurenine (NAK) or pharmaceutically acceptable salts thereof as the active ingredient.

  这项发明提供了一种治疗T细胞介导的疾病、退行性关节疾病或由血小板活化因子（PAF）介导的疾病的方法、组合物和试剂盒，包括向需要的动物施用含有N-乙酰基-酪氨酸（NAK）或其药学上可接受的盐作为活性成分的药物组合物的有效量。
• Nicotinamide compositions and the therapeutic use thereof
  申请人：APeT Holding B.V.

  公开号：US10881614B2

  公开（公告）日：2021-01-05

  The present invention relates to compositions and methods for the prophylaxis or treatment of deficiencies in essential amino acid absorption and metabolism and/or of a pathology or symptom associated there with. In particular the invention concerns the treatment and/or prevention of ADHD, ADD and autism spectrum disorders. The present inventors have developed a method for prophylaxis or treatment of such symptoms and/or pathologies associated with a deficiency in essential amino acid absorption and/or metabolism, which method, stated generally, relies on the administration of nicotinamide, typically in a long-acting formulation so as to overcome the deficiencies of existing formulations, which have proven unsuitable for effective treatment.

  本发明涉及预防或治疗必需氨基酸吸收和代谢缺陷和/或与之相关的病理或症状的组合物和方法。本发明尤其涉及多动症、注意力缺失症和自闭症谱系障碍的治疗和/或预防。本发明者已经开发出一种方法，用于预防或治疗与必需氨基酸吸收和/或代谢不足有关的症状和/或病理，一般来说，这种方法依赖于烟酰胺的给药，通常是长效制剂，以克服现有制剂的不足，现有制剂已被证明不适合有效治疗。
• Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
  申请人：DermBiont, Inc.

  公开号：US11040077B2

  公开（公告）日：2021-06-22

  Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

  本文公开了使用源自人类的 Lividum Janthinobacterium 的组合物和方法。组合物可改善皮肤健康。方法可包括在宿主或宿主区域（如皮肤或粘膜）上施用源于人的生发的Lividum Janthinobacterium，以最大限度地减少一种或多种微生物的存在，最大限度地提高治疗效果，和/或改善健康状况。减少病原微生物的方法可包括向表面施用一种组合物，该组合物包括来源于人类的Janthinobacterium lividum和一种可接受的载体。组合物和方法可包括益生元，以最大限度地提高生长和/或代谢物。组合物和方法可包括来源于人的猪蓝细菌代谢物，如violacein、prodigiosin、吲哚-3-甲醛、兰特益生菌和/或其他后益生菌。
• NICOTINAMIDE COMPOSITIONS AND THE THERAPEUTIC USE THEREOF
  申请人：APeT Holding B.V.

  公开号：EP2731609A1

  公开（公告）日：2014-05-21
• METHODS, KITS AND COMPOSITIONS FOR DIAGNOSING AND TREATING RENAL DISEASE
  申请人：Hill's Pet Nutrition, Inc.

  公开号：EP4018200A1

  公开（公告）日：2022-06-29